Media

Media enquiries can also be emailed to mediaenquiriesUK@ipsen.com. Please note that we are unable to respond to any non-media enquiries sent to this address.

_{ALL-UK-000455}
_{Date of preparation: June 2021}

4 results

October 11, 2021

Advanced kidney cancer patients in Scotland become amongst the first in world to access CABOMETYX®▼ (cabozantinib) in combination with OPDIVO® (nivolumab) via NHS Scotland, following SMC acceptance*

Press Releases

July 15, 2021

Ipsen shares results from innovative research partnership exploring young people’s attitudes to science

Press Releases

May 26, 2021

New campaign launches to break down taboos around prostate cancer treatment side effects

Press Releases

February 9, 2021

Ipsen and Mendelian Announce Landmark Partnership to Reshape Rare Disease Diagnosis using Pioneering MendelScan Technology

Press Releases

© Ipsen Group 2021